Timing note: Fortive’s official earnings call is scheduled for Wednesday, July 29, 2026, at 12:00 p.m. ET—today, rather than tomorrow. This preview assumes results have not yet been released. (investors.fortive.com)
Fortive enters Q2 with good operating momentum, favorable comparisons, and a meaningfully lower share count. The principal question is no longer whether the post-Ralliant company can grow earnings—it is whether management can demonstrate that mid-single-digit organic growth is becoming repeatable, rather than a product of selling-day benefits and easy comparisons.
The expected headline numbers are approximately:
| Q2 2026 | Consensus | Q2 2025 | Implied growth |
|---|---|---|---|
| Revenue | $1.08B | $1.016B | ~6% |
| Adjusted EPS | $0.71 | $0.58 | ~22% |
Consensus estimates vary slightly by provider, but roughly center on $1.08 billion of revenue and $0.71 of adjusted EPS. (tipranks.com)
At the July 28 close of $64.11, FTV has risen about 16% year to date and approximately 7% since the Q1 report. At roughly 21–22 times current 2026 EPS guidance, the stock is not priced for a bad quarter. A routine in-line result may therefore need constructive guidance and orders commentary to generate material upside.
Fortive’s Q1 results were strong:
Management reaffirmed full-year adjusted EPS guidance of $2.90–$3.00, but said results were trending toward the upper half. It also indicated that core growth was tracking toward the upper end of its 2%–3% range. (investors.fortive.com)
For Q2 specifically, management guided investors toward:
That puts consensus almost directly on top of management’s prior framework. The more important information will consequently be the composition and durability of growth—not a one- or two-cent EPS variance.
Q1’s 5.3% core growth included approximately 150 basis points from extra selling days, implying underlying growth closer to 4%. The segment effects were uneven:
| Q1 2026 | Reported core growth | Selling-day benefit | Approx. normalized growth |
|---|---|---|---|
| Intelligent Operating Solutions | 5.2% | ~100 bps | ~4% |
| Advanced Healthcare Solutions | 5.8% | ~300 bps | ~3% |
| Consolidated | 5.3% | ~150 bps | ~4% |
Q2 consensus revenue of $1.08 billion implies roughly 6.3% reported growth against the weak Q2 2025 comparison. Subtracting management’s expected 150-basis-point FX/M&A contribution suggests an implied core-growth hurdle near 5%, subject to rounding and actual acquisition timing.
That would represent genuine acceleration from Q1’s calendar-normalized result. If core growth is only 3%–4%, the headline revenue number could still look respectable, but investors may conclude that the business remains closer to its 2%–3% annual algorithm than management’s recent momentum commentary suggests.
IOS represents roughly 70% of revenue and an even larger proportion of segment EBITDA. Q2 2025 revenue was $697 million with a 33.8% adjusted EBITDA margin, making this the most important segment for both the top line and incremental margins. (investors.fortive.com)
Key areas to monitor:
Management has highlighted strong demand for Fluke’s new CertiFiber Max fiber-testing platform and potential pull-through into power quality, thermal imaging, battery testing and calibration products. The data-center opportunity covers both construction and the longer-lived maintenance cycle.
Investors should listen for:
A strong Fluke result is particularly important because management said Fluke’s Q1 book-to-bill exceeded one and orders grew faster than revenue.
ServiceChannel, Gordian and the broader FAL portfolio grew faster than IOS in Q1, supported by healthy ARR and retention metrics. Q2 includes an important state and local government spending period for Gordian.
Watch for:
Industrial Scientific’s Hardware-as-a-Service offering has been gaining share, with favorable demand in North America, Europe and the Middle East. Recurring-service growth would reinforce the argument that Fortive’s revenue mix is becoming more durable.
AHS generated $320 million of revenue in Q2 2025, with core revenue down 1.9%. The weak comparison reflected pressure on hospital capital spending, making Q2 2026 an important test of the recovery narrative. (investors.fortive.com)
The segment has three different demand profiles:
The ideal result would combine continued consumables and software strength with a clear sequential improvement in capital equipment. AHS can still report reasonable growth without a capital recovery because of its easy comparison, so management’s description of orders and customer budgets will matter more than the headline growth rate.
Also watch the “made-in-region” strategy in China and India. Management said these programs were beginning to help demand, but the benefits have not yet been quantified.
Q1 adjusted EBITDA margin expanded 140 basis points to 29.3%, even though gross margin fell approximately 100 basis points. The gross-margin decline was largely attributed to the net effect of tariffs.
Management’s prior timetable was:
Q2 2025 adjusted EBITDA margin was 28.4%, so a Q2 margin around 29.3% would represent approximately 90 basis points of expansion. That would be consistent with the annual framework.
Investors should separate:
A result driven primarily by lower corporate expenses and repurchases would be lower quality than one supported by stable gross margin and strong segment-level incrementals.
Current full-year guidance is:
| Metric | Existing outlook |
|---|---|
| Revenue | Around $4.3B |
| Core growth | 2%–3%, trending toward upper end |
| Adjusted EPS | $2.90–$3.00, trending toward upper half |
| Net interest expense | Just over $135M |
| Annual adjusted EBITDA-margin expansion | 50–100 bps |
An EPS result around $0.71 would put first-half adjusted EPS near $1.41. Fortive would then need approximately $1.49–$1.59 in the second half to reach its annual range.
Management previously said Q3 EPS should also be broadly similar to Q1, while Q4 faces four fewer selling days and a $15–$20 million revenue headwind. Q4 should nevertheless benefit from a lower expected tax rate, a smaller share count and the full effect of tariff countermeasures.
Simply reiterating “the upper half” of the EPS range would be consistent with prior commentary and is unlikely to qualify as a meaningful raise.
Fortive repurchased approximately $500 million of stock in Q1 at an average price of $56.21. Since the Ralliant separation, management has reduced the diluted share count by a little more than 10%, making repurchases a major component of EPS growth.
The buybacks were partly financed with commercial paper, and gross debt to adjusted EBITDA reached approximately 2.8 times at the end of Q1. In May, Fortive issued:
The proceeds were primarily intended to refinance $900 million of 3.15% notes due in June and other indebtedness. (investors.fortive.com)
Questions for the call include:
The repurchases have clearly created EPS accretion, but investors should monitor whether Fortive is using leverage to buy shares at increasingly higher valuations.
These are not formal forecasts, but a framework for judging the quality of the release:
This would be operationally sound, although the stock reaction could be muted given the recent appreciation.
FTV’s setup is constructive but less forgiving than it was in April. The company has:
But the stock’s rise and roughly 21–22 times guided earnings multiple mean investors are likely to demand evidence that the post-separation Fortive can sustain approximately 4%–5% organic growth with margin expansion.
The most important datapoints are therefore, in order:
A modest EPS beat generated by repurchases would be helpful but insufficient. The higher-quality outcome is a quarter showing broad-based volume growth, durable orders and segment-level margin improvement.